Verbenalin

Verbenalin is an iridoid glycoside found primarily in Verbena officinalis that exerts neuroprotective and organ-protective effects through modulation of oxidative stress pathways and inflammatory signaling. Its primary mechanisms involve inhibition of ferroptosis, upregulation of HIF-1α/HO-1 antioxidant pathways, and restoration of neurotrophic factor expression including BDNF in hippocampal tissue.

Origin & History

Verbenalin is an iridoid glycoside bioactive compound extracted from the aerial parts of Verbena officinalis L. (vervain), a perennial herb in the Verbenaceae family native to Europe, Asia, and North America. It is typically isolated through ethanol or aqueous extraction methods from the dried plant material.

Historical & Cultural Context

Verbena officinalis, the source of verbenalin, has been used in traditional Chinese medicine (including modern COVID-19 formulations like Xuanfeibaidu granules) and European herbalism for inflammation, liver conditions, respiratory issues, and infections. Historical applications include treating jaundice, edema, malaria, dysmenorrhea, and throat obstruction.

Health Benefits

• May protect kidney function during ischemia-reperfusion injury by inhibiting ferroptosis and upregulating HIF-1α/HO-1 pathways (preliminary animal evidence)
• Potentially reduces Alzheimer's disease markers including amyloid-beta and tau proteins while restoring BDNF levels in the hippocampus (preliminary animal evidence)
• May alleviate alcoholic liver damage by targeting oxidative stress and mitochondrial dysfunction via MDMX/PPARα pathways (preliminary animal evidence)
• Could protect against acute lung injury by suppressing inflammatory pyroptosis and NET formation through GPR18 receptor activation (preliminary animal evidence)
• May enhance natural killer (NK) cell efficiency by shortening target contact time without affecting proliferation (preliminary in-vitro evidence)

How It Works

Verbenalin activates the HIF-1α/HO-1 signaling axis, which suppresses ferroptosis — an iron-dependent form of programmed cell death — by reducing lipid peroxidation and preserving mitochondrial integrity in renal tubular cells. In neurological contexts, verbenalin appears to inhibit beta-secretase (BACE1) activity and tau hyperphosphorylation, reducing amyloid-beta plaque accumulation while simultaneously upregulating BDNF/TrkB signaling in the hippocampus. It also modulates NF-κB-driven neuroinflammation by downregulating pro-inflammatory cytokines including TNF-α and IL-1β.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on verbenalin; all available evidence comes from preclinical animal and cell studies. Key animal studies include mouse models of kidney injury (PMID: 41286690), sepsis-induced lung injury (PMID: 37315751), and alcoholic steatohepatitis (PMID: 36739928), with doses ranging from 10-200 mg/kg.

Clinical Summary

Current evidence for verbenalin is largely preclinical, derived from rodent models of ischemia-reperfusion injury and Alzheimer's disease rather than human clinical trials. In animal studies, verbenalin administration reduced serum creatinine and BUN markers of kidney injury by approximately 30–50% in ischemia-reperfusion models, with histological evidence of reduced tubular necrosis. Alzheimer's model rodents treated with verbenalin showed measurable decreases in hippocampal amyloid-beta deposits and improved Morris water maze performance, suggesting cognitive benefit. No peer-reviewed human randomized controlled trials have been published as of early 2025, making translation of these findings to clinical practice premature.

Nutritional Profile

Verbenalin (also known as verbenalol glucoside or cornin) is an iridoid glycoside, not a nutritional food source. It is a secondary plant metabolite and therefore does not possess a conventional macronutrient or micronutrient profile. Key biochemical details: • Chemical formula: C₁₇H₂₄O₁₀ • Molecular weight: ~388.37 g/mol • Classification: Iridoid glycoside (monoterpene-derived) • Primary natural sources: Verbena officinalis (common vervain), Verbena hastata (blue vervain), and Cornaceae species; typically present in aerial parts at concentrations ranging from approximately 0.1–2.0% dry weight depending on plant species, harvest time, and extraction method • Bioactive compound characteristics: Contains a glucose moiety linked to an iridoid aglycone (verbenalol); the glycosidic bond is hydrolyzed by intestinal β-glucosidases, releasing the active aglycone for absorption • Bioavailability notes: As an iridoid glycoside, oral bioavailability is generally considered low to moderate; the compound undergoes extensive first-pass metabolism and intestinal hydrolysis; the sugar moiety (glucose) enhances water solubility but may limit passive membrane permeation; studies suggest absorption is improved when administered in whole-plant extracts containing other polyphenols and organic acids that may modulate gut permeability and transporter activity • No meaningful content of macronutrients (protein, fat, carbohydrates, fiber), vitamins, or dietary minerals, as it is consumed in milligram-level pharmacological doses rather than as a food • Often co-occurs in plant extracts with other bioactive iridoids (hastatoside, aucubin), flavonoids (apigenin, luteolin), and phenylpropanoids (acteoside/verbascoside), which may contribute synergistic biological effects • Typical experimental doses in animal studies range from approximately 5–100 mg/kg body weight; no established human dietary reference intake or recommended dosage exists

Preparation & Dosage

No human dosage data exists. Animal studies used 10-20 mg/kg daily for kidney protection, 100-200 mg/kg for Alzheimer's models, with administration routes including oral gavage and intraperitoneal injection. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

HIF-1α activators, BDNF enhancers, PPARα agonists, GPX4 supporters, Antioxidants

Safety & Interactions

Verbenalin has not undergone formal human safety trials, so a comprehensive side effect profile has not been established. Animal studies have not reported overt toxicity at studied doses, but high-dose iridoid glycosides as a class can cause gastrointestinal irritation in some individuals. Verbenalin may theoretically potentiate anticoagulant medications such as warfarin due to its effects on oxidative and inflammatory pathways, though direct interaction data are lacking. Pregnant and breastfeeding women should avoid verbenalin supplements due to the absence of safety data, and individuals with iron metabolism disorders should use caution given its ferroptosis-modulating activity.